Mycobacterium Avium-intracellulare Infection Clinical Trial
OBJECTIVES: I. Determine the bacteriological activity of amithiozone against Mycobacterium
avium complex (MAC) pulmonary disease.
II. Define the ability of amithiozone to improve clinical outcomes in patients with MAC
infection.
III. Determine the safety and tolerance of amithiozone with chronic dosing in these
patients.
IV. Assess the contribution of clarithromycin, streptomycin, rifampin, ethambutol,
kanamycin, and amithiozone in the treatment of pulmonary MAC infection.
PROTOCOL OUTLINE: The is a randomized, open label study. All patients receive a core regimen
of clarithromycin and streptomycin. Patients are randomized into two treatment arms. Arm I
patients receive rifampin and ethambutol. Arm II patients receive amithiozone.
Patients are followed for one year to detect any relapse or other complications.
Patients not eligible for this randomized study may be entered on a short open label study
with amithiozone.
Completion date provided represents the completion date of the grant per OOPD records
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00000883 -
Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy
|
N/A | |
Completed |
NCT00111397 -
Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection
|
Phase 1 | |
Completed |
NCT00021567 -
A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections
|
Phase 2 | |
Completed |
NCT00001763 -
Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection
|
Phase 1 | |
Recruiting |
NCT05824988 -
Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease
|
||
Completed |
NCT00002122 -
A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients
|
Phase 3 | |
Completed |
NCT00002085 -
A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy
|
N/A | |
Completed |
NCT00000933 -
Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048
|
||
Completed |
NCT00002104 -
Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV
|
Phase 1 | |
Completed |
NCT00002101 -
A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo
|
Phase 3 | |
Completed |
NCT00002170 -
A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)
|
Phase 2 | |
Completed |
NCT00002309 -
A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients
|
N/A | |
Completed |
NCT00002058 -
A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease
|
N/A | |
Completed |
NCT00000641 -
A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.
|
Phase 2 | |
Completed |
NCT00000971 -
The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS
|
Phase 1 | |
Completed |
NCT00002032 -
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial
|
N/A | |
Completed |
NCT00000644 -
A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS
|
Phase 2 | |
Completed |
NCT00002140 -
A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients
|
Phase 3 | |
Completed |
NCT00001023 -
The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patients
|
N/A | |
Completed |
NCT00002267 -
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial
|
N/A |